Prot #AV-951-12-205: A Phase 2 Randomized, Double-Blind, Crossover, Controlled, Multi-Center, Subject Preference Study of Tivozanib Hydrochloride Versus Sunitinib in the Treatment of Subjects with Metastatic Renal Cell Carcinoma

    Project: Research project

    Project Details

    StatusFinished
    Effective start/end date10/19/1210/19/18

    Funding

    • AVEO Pharmaceuticals, Inc. (Prot #AV-951-12-205)